Chamber and committees

This information is not held centrally by The Scottish Government.

The rollout of transformational IT projects are a matter for Police Scotland. However, as outlined at the Scottish Police Authority’s Audit and Risk Committee on 17 January, the second phase of Core Operating Solutions is being implemented as expected and within the anticipated timescales.

The Scottish Government has invested £11.6 billion in policing since the creation of Police Scotland in 2013, with a further £1.45 billion to be invested in 2023-24, an increase of 6.3%.

The Veterans Mental Health & Wellbeing Action Plan was published in December 2021 and, through this, three key principles have been identified for future services: equal access to service; clear and timely pathways to correct help; and improving support to providers.

The new Implementation Board will work to implement these principles and ensure that veterans have parity of care, no matter where they are located in Scotland. The Implementation Board is chaired by Dr Charles Winstanley, a veteran with considerable experience in the NHS and in the third sector. The board includes Combat Stress, representatives from NHS Health Boards, Veterans First Point and Veterans Scotland.

I refer the member to the answer to question S6W-13903 on‎ 24 January 2023. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers .’

I refer the member to the answer to question S6W-13903 on 24 January 2023. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers .’

I refer the member to the answer to question S6W-13041 on 10 January 2023 . All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers .’

Planning authorities are required to maintain a Register of Enforcement containing details of any enforcement action taken by that authority, including notices issued under s.179 of the Town and Country Planning (Scotland) Act 1997. The Register of Enforcement is a public document and is published by the planning authority.

There is no requirement for a planning authority to inform the Scottish Government when any enforcement notice, including a notice under s.179 of the 1997 Act is issued. The Scottish Government therefore does not hold such information.

The NACCP last met in May 2021. As set out in the Implementation Plan for the Framework the NACCP has been replaced by the Pain Management Task force.

The Scottish Government does not hold this information centrally.

In Scotland, the Scottish Medicines Consortium (SMC) appraises the clinical and cost-effectiveness of newly-licensed medicines. Making decisions about whether or not to recommend routine access to new medicines is a complex task and the SMC bases its decisions on the best available evidence provided to it. Following a full submission from the submitting company, Aimmune Therapeutics, on 10 October 2022, the SMC published “not recommended” advice for Health Boards on the routine use of Palforzia ® in NHS Scotland. The submission received did not present a sufficiently robust economic analysis to gain acceptance by the SMC.

By way of an update, Aimmune Therapeutics has indicated its intention to make a resubmission to the SMC.If they do, information on the specific timelines for the reassessment will be available via the search facility available on the home page of the SMC’s website here . There is a fast-track resubmission option, which reduces the normal assessment timeline.

In the meantime, Health Boards have procedures in place using the Peer Approved Clinical System “PACS Tier Two” process, for clinicians to request the use of licensed medicines on a ‘case-by-case’ basis for individual patients, when the treating clinician considers that there would be significant clinical benefit for a patient.